Publication: 3667

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 41 (3) 618-628
Year:
2023
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Preliminary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
12
Parents:
3250  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
AstraZeneca, Eli Lilly, and GSK (Novartis)  
Grants:
U10CA180821, U10CA180882, UG1CA233180, UG1CA233184, UG1CA233193, UG1CA233196, UG1CA233320, UG1CA233324, UG1CA233331, UG1CA233339, UG1CA232760, UG1CA233290, and U10CA180888 (SWOG).  
Corr. Author:
 
Authors:
                                                                                           
Networks:
CA088, CA249, CA824, COLUMBIA, CORA, FL028, FL086, LAPS-CO070, LAPS-IL036, LAPS-MA036, LAPS-MD017, LAPS-MN026, LAPS-MO011, LAPS-NH012, LAPS-NY016, LAPS-OH007, LAPS-OK003, MA011, MCRC, NE003, OH070, RI005, VA002, VA009, VT004   
Study
Alliance-A071401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Humans, Focal Adhesion Protein-Tyrosine Kinases, Meningeal Neoplasms, Meningioma, Mutation, Neoplasm Recurrence, Local